新股消息 | 科兴制药(688136.SH)递表港交所

Core Viewpoint - The company, Sinovac Biotech Ltd., has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Jinshi International as its sole sponsor. The company is recognized as one of the earliest biopharmaceutical enterprises in China, focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1]. Group 1 - Sinovac Biotech is an innovation-driven and internationally developed biopharmaceutical company [1]. - The company is one of the first biopharmaceutical enterprises established in China and is a key industrialization base for the national "863" program [1]. - The main revenue sources during the reporting period include four self-commercialized products and two introduced products [1]. Group 2 - The self-commercialized products include SINOGEN (human interferon α1b injection), EPOSINO (human erythropoietin injection), WHITE-C (human granulocyte colony-stimulating factor injection), and CLOBICO (Clostridium butyricum live bacteria powder/capsule) [1]. - The introduced products are Apexelsin (paclitaxel injection) and Reminton (infliximab injection) [1].